Liposome Company Abelcet expands anti-fungal indications with Oct. 18 sNDA approval.
Executive Summary
THE LIPOSOME COMPANY ABELCET ANTI-FUNGAL INDICATIONS BROADENED to include use against several additional types of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. The Oct. 18 approval expands Abelcet's listed indications to include candidiasis, cryptococcal meningitis, zygomycosis, and fusariosis. The company submitted the supplemental NDA in April.